Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 1/20 | 0.69 |
| ▸ | CSNK2A2 | P19784 | 11/20 | 0.55 |
| ▸ | CSNK2B | P67870 | 11/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 11/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.49 |
| ▸ | PTGES | O14684 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3014989 | 0.93 | CYP2C8 (0.81) | CYP2C8CSNK2A2CSNK2BCSNK2A1ESR2 | |
| SCHEMBL3002395 | 0.89 | CYP2C8 (0.61) | CYP2C8CSNK2A2CSNK2BCSNK2A1ESR2 | |
| SCHEMBL3013908 | 0.89 | CYP2C8 (0.86) | CYP2C8ALOX5PTGESMEN1MAPT | |
| SCHEMBL3015418 | 0.87 | ALOX5 (0.65) | CYP2C8CSNK2A2CSNK2BCSNK2A1ESR2 | |
| SCHEMBL3012615 | 0.85 | FFAR1 (0.63) | CYP2C8CSNK2A2CSNK2BCSNK2A1ESR2 | |
| SCHEMBL3001663 | 0.84 | CYP2C8 (0.55) | CYP2C8CSNK2A2CSNK2BCSNK2A1ESR2 | |
| SCHEMBL3008716 | 0.82 | CYP2C8 (0.53) | CYP2C8CSNK2A2CSNK2BCSNK2A1ESR2 | |
| SCHEMBL3007045 | 0.82 | GAA (0.61) | CYP2C8CSNK2A2CSNK2BCSNK2A1ESR2 | |
| SCHEMBL3002082 | 0.82 | CYP2C8 (1.00) | CYP2C8ALOX5PTGESMEN1MAPT | |
| SCHEMBL30992329 | 0.82 | CYP2C8 (1.00) | CYP2C8ALOX5PTGESMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069321-B1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | MEDIFRON DBT CO LTD (KR) | 2016-04-13 | — | — | EP | claimed |
| US-20100197685-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DIGITAL BIOTECH CO., LTD (KR) | 2010-08-05 | — | — | US | claimed |
| EP-2069321-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | Digital Biotech Co., Ltd. (KR) | 2009-06-17 | — | — | EP | claimed |
| WO-2008041826-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DIGITAL BIOTECH CO., LTD (KR) | 2008-04-10 | — | — | WO | claimed |
| EP-2069321-B1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | MEDIFRON DBT CO LTD (KR) | 2016-04-13 | — | — | EP | disclosed |
| US-8580848-B2 | Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-11-12 | — | — | US | disclosed |
| US-8507553-B2 | Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-08-13 | — | — | US | disclosed |
| US-8455542-B2 | Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-06-04 | — | — | US | disclosed |
| US-20120259006-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DAEWOONG PHARMACEUTICAL CO., LTD (KR) | 2012-10-11 | — | — | US | disclosed |
| US-20120245225-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DAEWOONG PHARMACEUTICAL CO., LTD (KR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245165-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DAEWOONG PHARMACEUTICAL CO., LTD (KR) | 2012-09-27 | — | — | US | disclosed |
| US-8263649-B2 | Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof | MEDIFRON DBT CO., LTD. (KR) | 2012-09-11 | — | — | US | disclosed |
| US-20100197685-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DIGITAL BIOTECH CO., LTD (KR) | 2010-08-05 | — | — | US | disclosed |
| EP-2069321-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | Digital Biotech Co., Ltd. (KR) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008041826-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DIGITAL BIOTECH CO., LTD (KR) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197685-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | APP, BACE1, PSEN1 | CYP2C8 3557/4885CSNK2A2 2506/4885CSNK2B 2826/4885 |
| US-20120259006-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | APP, BACE1, PSEN1 | CYP2C8 3557/4885CSNK2A2 2506/4885CSNK2B 2826/4885 |
| US-20120245165-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | APP, BACE1, PSEN1 | CYP2C8 3557/4885CSNK2A2 2506/4885CSNK2B 2826/4885 |
| US-20120245225-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | APP, BACE1, PSEN1 | CYP2C8 3557/4885CSNK2A2 2506/4885CSNK2B 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.